Carol Michelle*
Vasculitis, a group of autoimmune disorders characterized by inflammation of blood vessels, poses significant challenges in management due to its heterogeneity and potential for organ damage. While traditional immunosuppressive therapies have been instrumental in controlling disease activity, emerging biologic therapies offer targeted interventions that hold promise in improving outcomes for patients with vasculitis. This article reviews the latest advancements in biologic therapies, including monoclonal antibodies, cytokine inhibitors, and targeted immunomodulators, focusing on their efficacy and safety profiles based on clinical evidence and real-world experience. Despite the progress made, challenges such as long-term safety, optimization of treatment strategies, and access barriers persist. Future research directions, including personalized treatment approaches and combination therapies, aim to address these challenges and further enhance the management of vasculitis. By understanding the evolving landscape of biologic therapies, healthcare providers can make informed decisions and improve outcomes for patients with this complex autoimmune condition.
ఈ కథనాన్ని భాగస్వామ్యం చేయండి
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 